BioCentury | Dec 31, 2020
Finance

Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

...5Y Capital and Redpoint China Ventures, respectively. Source Code Capital, BAI Capital, Gaorong Capital and DCM...
BioCentury | Oct 5, 2020
Deals

Bristol Myers adds CV therapy through $13.1B MyoKardia takeout

...two other clinical programs: danicamtiv (MYK-491), which is in Phase II testing for dilated cardiomyopathy (DCM...
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

...and corporate compliance at Gritstone Oncology Inc. (NASDAQ:GRTS); Chao is co-founder and general partner of DCM...
BioCentury | Aug 14, 2019
Finance

Renovacor raises $11M to advance gene therapy for rare cardiomyopathy

...developing a gene therapy that uses an adeno-associated viral (AAV) serotype 9 vector to address DCM...
...in patients with mutated BCL2-associated athanogene 3 (BAG3; CAIR-1). About 35,000 of the 3 million DCM...
BioCentury | Nov 17, 2018
Product Development

MyoKardia’s myosin mechanism deconvolution

...to begin clinical testing of ACT-1 in 1H21 to treat genetic forms of dilated cardiomyopathy (DCM...
BioCentury | Nov 2, 2018
Clinical News

MyoKardia's heart failure candidate shows proof of mechanism in Phase Ia

...NYSE:SNY) and MyoKardia are partnered to co-develop the biotech’s therapies for hypertrophic cardiomyopathy (HCM) and DCM...
...Status: Phase Ia data Milestone: Phase Ib data (4Q18); Phase IIa data (2019) Brian Moy MYK-491, SAR440181, dcm-1 MyoKardia...
BioCentury | Mar 16, 2018
Clinical News

MyoKardia's mavacamten meets in low-dose cohort of Phase II for cardiomyopathy

...partnered to co-develop two MyoKardia programs for HCM, including mavacamten, and another for dilated cardiomyopathy (DCM...
BioCentury | Aug 11, 2017
Clinical News

MyoKardia's mavacamten meets in Phase II for HCM

...partnered to co-develop 2 MyoKardia programs for HCM, including mavacamten, and another for dilated cardiomyopathy (DCM...
BioCentury | Aug 7, 2017
Clinical News

MyoKardia to raise funds after reporting HCM data

...partnered to co-develop two MyoKardia programs for HCM, including mavacamten, and another for dilated cardiomyopathy (DCM). Jaime...
BioCentury | May 19, 2017
Company News

ICT gets rights to Vericel programs in Asia, including China

...which completed a Phase IIb trial to treat heart failure due to ischemic dilated cardiomyopathy (DCM...
Items per page:
1 - 10 of 61
BioCentury | Dec 31, 2020
Finance

Dec. 30 Quick Takes: Transcenta leads year-end crop of China venture rounds

...5Y Capital and Redpoint China Ventures, respectively. Source Code Capital, BAI Capital, Gaorong Capital and DCM...
BioCentury | Oct 5, 2020
Deals

Bristol Myers adds CV therapy through $13.1B MyoKardia takeout

...two other clinical programs: danicamtiv (MYK-491), which is in Phase II testing for dilated cardiomyopathy (DCM...
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

...and corporate compliance at Gritstone Oncology Inc. (NASDAQ:GRTS); Chao is co-founder and general partner of DCM...
BioCentury | Aug 14, 2019
Finance

Renovacor raises $11M to advance gene therapy for rare cardiomyopathy

...developing a gene therapy that uses an adeno-associated viral (AAV) serotype 9 vector to address DCM...
...in patients with mutated BCL2-associated athanogene 3 (BAG3; CAIR-1). About 35,000 of the 3 million DCM...
BioCentury | Nov 17, 2018
Product Development

MyoKardia’s myosin mechanism deconvolution

...to begin clinical testing of ACT-1 in 1H21 to treat genetic forms of dilated cardiomyopathy (DCM...
BioCentury | Nov 2, 2018
Clinical News

MyoKardia's heart failure candidate shows proof of mechanism in Phase Ia

...NYSE:SNY) and MyoKardia are partnered to co-develop the biotech’s therapies for hypertrophic cardiomyopathy (HCM) and DCM...
...Status: Phase Ia data Milestone: Phase Ib data (4Q18); Phase IIa data (2019) Brian Moy MYK-491, SAR440181, dcm-1 MyoKardia...
BioCentury | Mar 16, 2018
Clinical News

MyoKardia's mavacamten meets in low-dose cohort of Phase II for cardiomyopathy

...partnered to co-develop two MyoKardia programs for HCM, including mavacamten, and another for dilated cardiomyopathy (DCM...
BioCentury | Aug 11, 2017
Clinical News

MyoKardia's mavacamten meets in Phase II for HCM

...partnered to co-develop 2 MyoKardia programs for HCM, including mavacamten, and another for dilated cardiomyopathy (DCM...
BioCentury | Aug 7, 2017
Clinical News

MyoKardia to raise funds after reporting HCM data

...partnered to co-develop two MyoKardia programs for HCM, including mavacamten, and another for dilated cardiomyopathy (DCM). Jaime...
BioCentury | May 19, 2017
Company News

ICT gets rights to Vericel programs in Asia, including China

...which completed a Phase IIb trial to treat heart failure due to ischemic dilated cardiomyopathy (DCM...
Items per page:
1 - 10 of 61